NAD+ for fatigue: evidence, expectations and your next step

Describe what “tired” means in your day

Write down when the change started and what it prevents you from doing. Are you sleepy despite enough time in bed, physically exhausted after ordinary activity, or having trouble concentrating? Note sleep changes, recent illness, medication changes and whether the pattern is getting worse. These details help a clinician decide what to investigate.

Persistent fatigue can have several explanations, including sleep disorders, medication effects, anemia and thyroid disease. A clinician may recommend an examination or selected tests based on your history. A product-focused consultation should still leave room for that evaluation, rather than treating the symptom as evidence of low NAD+.

Read: MedlinePlus: Fatigue.

NAD+ biology explains interest, not your diagnosis

NAD+ participates in cellular metabolism, which makes it an understandable subject of energy research. But a molecule’s normal function does not establish that supplementing it will relieve a particular person’s fatigue. “Cellular energy” and feeling more capable through an ordinary day are different things to measure.

One frequently cited human study followed NAD-related metabolites during a six-hour IV infusion. It involved eleven men, eight of whom received NAD+. The study helps describe what happened to the administered substance. It was not a trial showing improved workday energy, exercise recovery or lifespan.

Read: Grant et al. NAD+ metabolism during a six-hour IV infusion.

Ask whether the study matches the offered route

An IV infusion enters a vein. A subcutaneous injection places medicine beneath the skin. A nasal spray is another route again. Those differences affect the questions researchers need to answer. An infusion study cannot establish that an at-home injection or nasal spray has the same effect.

A newer randomized IV study in people with heart failure from ischemic cardiomyopathy reported an improvement in a measure of cardiac pumping function. Participants had a diagnosed disease and received NAD+ alongside established care. It does not establish a benefit for ordinary fatigue or validate the compounded subcutaneous and nasal preparations discussed here.

Read: Grant et al. NAD+ metabolism during a six-hour IV infusion; Yu et al. Intravenous NAD+ in ischemic cardiomyopathy.

Make a treatment proposal concrete before committing

If a clinician proposes NAD+, ask which symptom the plan aims to change, what evidence fits your route and how the response will be reviewed. Agree on a practical baseline, such as the activities fatigue currently interrupts, and a date to revisit the decision. Track other changes in sleep, training or medication so the interpretation stays useful.

Also clarify the full course cost, supplies, storage instructions and access to follow-up. A response diary can inform care, but it cannot prove that NAD+ caused an improvement. Feeling no meaningful benefit is information too; the review should allow a discussion about changing or stopping treatment.

Keep quality and persistent symptoms in the same conversation

FDA has warned about unsuitable food-grade ingredients used in sterile NAD+ compounding and has received reports of severe chills, shaking, vomiting and fatigue consistent with excessive endotoxin exposure. That warning does not mean every product is affected. It does make the actual dispensing pharmacy, preparation and instructions relevant to the decision.

Compounded NAD+ products have not undergone FDA approval. If fatigue persists or worsens, return to the clinical evaluation instead of assuming you need more NAD+ or another peptide. The useful outcome is a plan that helps explain and address the problem you came with.

Read: FDA: Ingredients suitable for sterile compounding; FDA: Compounding questions and answers; MedlinePlus: Fatigue.